Skip to main content

Advertisement

SpringerLink
Log in

Antiretrovirale Therapieregime

Antiviral treatment regimens

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Die Verfügbarkeit und Anwendung von wirksamen antiretroviralen Therapieregimen haben die Mortalität und Morbidität der HIV-Infektion dramatisch gesenkt. Die weitestgehende Hemmung der Virusreplikation durch eine antiretrovirale Therapie (ART) verhindert die Krankheitsprogression sowie die Resistenzentwicklung, führt zur Rückbildung HIV-bedingter Symptome und zur klinisch relevanten Immunrekonstitution. Mittlerweile sind über 20 antiretrovirale Substanzen in 4 Medikamentenklassen zugelassen. Die Infektion ist dadurch besser behandelbar, die ART ist jedoch schwieriger geworden. Eine Vielzahl von Kombinationen ist denkbar, von denen nur eine kleine Zahl sinnvoll ist. Indikationsstellung, Auswahl der individuell am besten geeigneten Therapie, Beratung des Patienten und Therapiemonitoring erfordern ein hohes Maß an Erfahrung im Umgang mit HIV-infizierten Patienten. Unter den modernen Therapieregimen wird beim adhärenten Patienten nur noch selten ein virologisches Versagen beobachtet.

Abstract

The availability and use of effective antiretroviral combination therapies has dramatically decreased the morbidity and mortality of HIV infection. Almost complete suppression of viral replication by antiretroviral therapy prevents disease progression and development of resistance, as well as leading to both regression of HIV-associated symptoms and clinically relevant immune reconstitution. More than 20 antiretroviral substances in four classes have been approved. As a result of the broad therapeutic options, HIV infection can be better treated. Although a high number of combinations can be conceived, only a small number is actually applicable. The decisions to start, monitor and change therapy have become even more difficult. The indication for treatment, the selection of the most suitable therapy for an individual, the counseling of the patient, and the monitoring of the success of treatment demand a high level of knowledge and experience. Virologic failures of modern antiretroviral therapy regimens are rare in adherent patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V (2004) Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 18(6): 960–963

    Article  PubMed  Google Scholar 

  2. Carr A, Samaras K, Burton S et al. (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12(7): F51–58

    Article  PubMed  Google Scholar 

  3. Carr A, Miller J, Law M, Cooper DA (2000) A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14(3): F25–32

    Article  PubMed  Google Scholar 

  4. Concorde Team (1994) MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet 343(8902): 871–881

    Article  PubMed  Google Scholar 

  5. d’Arminio A, Sabin CA, Phillips AN et al. (2004) Cardio- and cerebrovascular events in HIV-infected persons. AIDS 18(13): 1811–1817

    PubMed  Google Scholar 

  6. DeJesus E, Herrera G, Teofilo E et al. (2004) Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 39(7): 1038–1046

    Article  PubMed  Google Scholar 

  7. Delta-Team (1996) A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet 348(9023): 283–291

    Article  PubMed  Google Scholar 

  8. Durant J, Clevenbergh P, Garraffo R et al. (2000) Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 14(10): 1333–1339

    Article  PubMed  Google Scholar 

  9. Finzi D, Blankson J, Siliciano JD et al. (1999) Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5(5): 512–517

    Article  PubMed  Google Scholar 

  10. Fischl MA, Ribaudo HJ, Collier AC et al. (2003) A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 188(5): 625–634

    Article  PubMed  Google Scholar 

  11. Garcia-Gasco P (2006) 48-weeks of the RESIST trials. AIDS Rev 8(1): 45

    PubMed  Google Scholar 

  12. Gonzalez de Requena D, Nunez M, Jimenez-Nacher I, Soriano V (2002) Liver toxicity caused by nevirapine. AIDS 16(2): 290–291

    Article  PubMed  Google Scholar 

  13. Gulick RM, Mellors JW, Havlir D et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337(11): 734–739

    Article  PubMed  Google Scholar 

  14. Gulick RM, Ribaudo HJ, Shikuma CM et al. (2004) Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 350(18): 1850–1861

    Article  PubMed  Google Scholar 

  15. Hammer SM, Vaida F, Bennett KK et al. (2002) Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 288(2): 169–180

    Article  PubMed  Google Scholar 

  16. Harrington M, Carpenter CC (2000) Hit HIV-1 hard, but only when necessary. Lancet 355(9221): 2147–2152

    Article  PubMed  Google Scholar 

  17. Ho DD (1995) Time to hit HIV, early and hard. N Engl J Med 333(7): 450–451

    Article  PubMed  Google Scholar 

  18. Kempf DJ, Marsh KC, Kumar G et al. (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41(3): 654–660

    PubMed  Google Scholar 

  19. Laessig KA, Lewis LL, Hammerstrom TS (2006) Tenofovir DF and emtricitabine vs. zidovudine and lamivudine. N Engl J Med 354(23): 2506–2508; author reply 2506–2508

    Article  Google Scholar 

  20. Lazzarin A, Clotet B, Cooper D et al. (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348(22): 2186–2195

    Article  PubMed  Google Scholar 

  21. Mellors JW, Munoz A, Giorgi JV et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126(12): 946–954

    PubMed  Google Scholar 

  22. Mocroft A, Katlama C, Johnson AM et al. (2000) AIDS across Europe, 1994–98: the EuroSIDA study. Lancet 356(9226): 291–296

    Article  PubMed  Google Scholar 

  23. Mocroft A, Youle M, Moore A et al. (2001) Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 15(2): 185–194

    Article  PubMed  Google Scholar 

  24. Montaner JS, Harrigan PR, Jahnke N et al. (2001) Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens. AIDS 15(1): 61–69

    Article  PubMed  Google Scholar 

  25. Raboud JM, Montaner JS, Conway B et al. (1998) Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 12(13): 1619–1624

    Article  PubMed  Google Scholar 

  26. Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM (2003) Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 83(1): 1–9

    Article  PubMed  Google Scholar 

  27. Salzberger B, Marcus U, Vielhaber B et al. (2004) German-Austrian recommendations for the antiretroviral therapy of HIV-infection (status May 2004). Eur J Med Res 9(11): 491–504

    PubMed  Google Scholar 

  28. Staszewski S, Morales-Ramirez J, Tashima KT et al. (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 341(25): 1865–1873

    Article  PubMed  Google Scholar 

  29. Walmsley S, Bernstein B, King M et al. (2002) Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346(26): 2039–2046

    Article  PubMed  Google Scholar 

  30. Wood E, Hogg RS, Yip B et al. (2004) The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 35(3): 261–268

    PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf eine Verbindung mit folgender Firma/Firmen hin: Teilnahme an zahlreichen Advisory Boards and Referent bei Veranstaltungen verschiedener Pharmaunternehmen

Author information

Authors and Affiliations

  1. Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Hufelandstraße 55, 45122 , Essen

    S. Esser

Authors
  1. S. Esser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Esser.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Esser, S. Antiretrovirale Therapieregime. Hautarzt 57, 961–968 (2006). https://doi.org/10.1007/s00105-006-1224-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-006-1224-6

Schlüsselwörter

Keywords

Search

Navigation